Sunitinib (SU11248; sutent), an antiangiogenic drug, was effective at inhibiting cellular proliferation and in combination with HIF1 α and enolase siRNA's indicated a synergistic antitumor activity, with a reduction in tumor nodule and tumor microvessel density. This evidence concerns the gene HIF1A and neoplasm.